Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):213–220. doi: 10.1097/QAI.0000000000001181

Table 1.

Baseline characteristics for nested case-control study participants, overall and stratified by TB recurrence outcome.

Characteristic All (n=24) TB recurrence (n=12) No TB recurrence (n=12)

Age in years at pre-ART; Mean (SD) 34.7 (6.11) 34.2 (5.73) 35.2 (6.67)
 Min to max 24 – 47 24 – 43 24 – 47

Female; n (%) 16 (66.7%) 8 (66.7%) 8 (66.7%)

Integrated arm; n (%) 16 (66.7%) 8 (66.7%) 8 (66.7%)

Previous history of TB; n (%) 14 (58.3%) 7 (58.3%) 7 (58.3%)

Pre-ART CD4 count, cells/μl; Mean (SD) 113 (72.06) 114 (73.85) 113 (73.50)
 Min to max 11 – 237 11 – 237 11 – 230

Pre-ART Log viral load, copies/ml; Mean (SD) 5.10 (0.83) 5.14 (0.70) 5.08 (1.00)
 Min to max 2.60 – 6.18 3.62 – 6.15 2.60 – 6.18

Current time on ARVs in years*; Median (IQR) 2.5 (1.9 – 3.6) 3.1 (1.4 – 1.3) 2.5 (0.7 – 1.6)

Current CD4 count, cells/μl; Mean (SD) 453 (435.35) 466 (604.73) 439 (119.55)
Min to max 14 – 2188 14 – 2188 271 – 671

Current CD4 count, cells/μl; Median (IQR) 354 (271 – 519) 289 (105 – 470) 423 (335 – 536)
Min to max 14 – 2188 14 – 2188 271 – 671

Current viral load suppressed**; n/N (%) 19/23 (82.6%) 8/12 (66.7%) 11/11 (100%)

Weight, kg; Mean (SD) 58.2 (8.75) 59.1 (9.16) 57.3 (8.62)

Body mass index; Mean (SD) 21.6 (3.42) 21.9 (3.62) 21.4 (3.36)

Cavitory disease at occurrence; n (%)

 No 16 (66.7%) 7 (58.3%) 9 (75.0%)

 One lung 5 (20.8%) 2 (16.7%) 3 (25.0%)

 Both lungs 3 (12.5%) 3 (25.0%) 0 (0.0%)

Infiltrates at occurrence; n (%)

 No 0 (0.0%) 0 (0.0%) 0 (0.0%)

 One lung 7 (29.2%) 1 (8.3%) 6 (50.0%)

 Both lungs 17 (70.8%) 11 (91.7%) 6 (50.0%)

Adenopathy at occurrence; n (%)

 No 23 (95.8%) 12 (100%) 11 (91.7%)

 One lung 1 (4.2%) 0 (0.0%) 1 (8.3%)

 Both lungs 0 (0.0%) 0 (0.0%) 0 (0.0%)

Pleural infusion at occurrence; n (%)

 No 21 (87.5%) 12 (100%) 9 (75.0%)

 One lung 3 (12.5%) 0 (0.0%) 3 (25.0%)

 Both lungs 0 (0.0%) 0 (0.0%) 0 (0.0%)
*

One TB recurrence case was not on ARVs at the time of enrolment on TRUTH and the pre-TB time point was a month prior to initiating treatment.

**

One patient, who did not experience TB recurrence, did not have VL data available at the first time point measured. Current refers to the very first time-point CD4 and VL were measured and duration of time on ARVs in this substudy.